Mark Couttie shares his thoughts on a common challenge facing the Pharma and Life Sciences industry.
I recently had the privilege of joining a senior leadership off-site in a global life sciences organisation. It was one of those rare environments where I could feel both the weight and excitement of ambition, along with the honesty of self-reflection and the scale of the challenge ahead in the room.
What struck me most wasn’t any single presentation, but the common thread running through the whole day. From the future of manufacturing, with its shift from batch to continuous, increasing regulatory complexity, and rapid advances in AI and technology; through to leadership conversations about capability, priorities, and the very real question of “what do we stop?”, the common thread was the challenge of “execution at scale”.
Across the pharmaceutical and life sciences industry, organisations are facing similar challenges:
- The need to innovate – more products needed and with a faster speed to market
- The requirement to operate with absolute precision and compliance
- The pressure to do more with finite capacity
- The expectation to create a differentiated employee experience to keep hold of the very best talent
Individually, none of these are new. Collectively, they are stretching organisations in ways that traditional operating models simply weren’t designed to handle.
In almost every growth or change story I’ve seen, the constraint isn’t intent or even talent. It’s capacity. Leaders are asking teams to be smarter, faster and more precise, but without fundamentally changing how the work gets done, what gets prioritised, and critically, what gets stopped. Simply adding more initiatives into an already full system doesn’t create progress, it creates friction.
Another theme that stood out for me was the increasing maturity around culture.
Not culture as a set of values on a wall, but as practical daily work behaviours where every strength has a potential downside:
- Collaboration can become consensus paralysis
- Accountability can become blame
- Pace can become short-termism
It’s important to treat culture not as a “soft” topic, but as a set of habits & behaviours that are performance levers, ones that are actively measured, coached, and aligned to strategy.
So what needs to change?
In my experience at Unleash & Engage, organisations in this sector unleash disproportionate levels of performance when they focus on three things:
1. Creating space before adding more
People need to relentlessly prioritise and remove or re-distribute work. This can no longer be optional, it needs to be a leadership discipline.
2. Translating strategy into daily behaviour
There needs to be clarity on what great looks like at every level. Not just what needs to be achieved, but how it needs to be delivered day-to-day.
3. Building leaders who can operate in tension
Leaders need to learn how to balance pace with precision, innovation with compliance, and performance with humanity.
Final thought
The life sciences organisations that will win over the next decade won’t be those with the best strategy on paper. It will be the ones that create the capacity, clarity, and behavioural discipline to actually deliver it.
Winning is about doing more. And this can only be sustainably achieved by doing what matters better than anyone else.